Manufacturer record
Mancare Laboratories Pvt. Ltd: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
18 batches manufactured by Mancare Laboratories Pvt. Ltd (Uttarakhand) were declared Not of Standard Quality between March 2024 and July 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
18 records linked to Mancare Laboratories Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Albendazole Tablets IP 400mg | MT251013Mfg 2025-10 · Exp 2027-09 | DissolutionDissolution | SDTL, RaipurState lab | Jul 2026 |
| Serratiopeptidase Tablets I P 10 mg | MT260002Mfg 2026-01 · Exp 2027-12 | It fails the test Disintegration as per IPDisintegration | RDTL ErnakulamState lab | Jun 2026 |
| Albendazole Tablets IP 400 mg | MT250979Mfg 2025-10 · Exp 2027-09 | The sample does not conform to IP with respect to test for Dissolution and Assay of AlbendazoleAssay | CDL KolkataCDSCO lab | Jun 2026 |
| Albendazole Tablets IP 400 mg | MT250998Mfg 2025-10 · Exp 2027-09 | The sample does not conform to I.P. with respect to test for DissolutionDissolution | CDL, KolkataCDSCO lab | Apr 2026 |
| Albendazole Tablets I.P. 400 mg | MT250995Mfg 2025-10 · Exp 2027-09 | The sample does not conform to I.P. with respect to test for Dissolution.Dissolution | CDL, KolkataCDSCO lab | Apr 2026 |
| Albendazole Tablets I.P. 400 mg | MT250996Mfg 2025-10 · Exp 2027-09 | The sample does not conform to I.P. with respect to test for Dissolution.Dissolution | CDL, KolkataCDSCO lab | Apr 2026 |
| Albendazole Tablets I.P. 400 mg | MT250994Mfg 2025-10 · Exp 2027-09 | The sample does not conform to I.P. with respect to test for DissolutionDissolution | CDL, KolkataCDSCO lab | Apr 2026 |
| Serratiopeptidase Tablets IP | MT250227Mfg 2025-02 · Exp 2027-01 | DisintegrationDisintegration | RDTL, ErnakulamState lab | Mar 2026 |
| Albendazole Tablets IP 400 mg | MT250971Mfg 2025-10 · Exp 2027-09 | DissolutionDissolution | SDTL Raipur ChhattisgarhState lab | Dec 2025 |
| Albendazole Tablets IP 400 mg | MT250990Mfg 2025-10 · Exp 2027-09 | DissolutionDissolution | SDTL Raipur ChhattisgarhState lab | Dec 2025 |
| Albendazole Tablets IP 400 mg | MT250998Mfg 2025-10 · Exp 2027-09 | DissolutionDissolution | SDTL Raipur ChhattisgarhState lab | Dec 2025 |
| Albendazole Tablets IP 400 mg | MT250987Mfg 2025-10 · Exp 2027-09 | DissolutionDissolution | SDTL Raipur ChhattisgarhState lab | Dec 2025 |
| Albendazole Tablets IP 400 mg | MT250981Mfg 2025-10 · Exp 2027-09 | DissolutionDissolution | SDTL Raipur ChhattisgarhState lab | Dec 2025 |
| Albendazole Tablets IP 400 mg | MT250989Mfg 2025-10 · Exp 2027-09 | DissolutionDissolution | SDTL Raipur ChhattisgarhState lab | Dec 2025 |
| Albendazole Tablets IP 400 mg | MT251010Mfg 2025-10 · Exp 2027-09 | DissolutionDissolution | SDTL Raipur ChhattisgarhState lab | Dec 2025 |
| Cefpodoxime Proxetil Tablets IP 200mg | MBT 24019Mfg 2024-06 · Exp 2026-05 | It fails the test Dissolution as per IPDissolution | DTL, Thiruvananthapuram, KeralaState lab | Oct 2025 |
| Pantoprazole Gastro- Resistant Tablets IP 40 mg. | MT240578Mfg 2024-08 · Exp 2026-07 | Dissolution in Buffer StageDissolution | CDL KolkataCDSCO lab | Apr 2025 |
| Co- Trimoxazole Oral Suspension I.P. (Altoprim Suspension) | ML-4943Mfg 2022-12 · Exp 2024-11 | pHpH | RDTL GuwahatiState lab | Mar 2024 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.